Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423721 | 0.88 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL136259 | 0.87 | KDM4E (0.60) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL135158 | 0.87 | KDM4E (0.60) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL620485 | 0.87 | GABRP (0.66) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL8510497 | 0.83 | KMT2A (0.49) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL5505525 | 0.81 | MAPT (0.61) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL11580712 | 0.77 | HPGD (0.56) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL3916185 | 0.76 | KDM4E (1.00) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL8191450 | 0.75 | KDM4E (0.98) | KDM4EALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL11476938 | 0.75 | ELANE (0.63) | KDM4EALDH1A1HPGDGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| EP-2640729-A1 | INHIBITORS OF HIV REPLICATION | VIIV Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | KDM4E 917/4885ALDH1A1 4304/4885HPGD 2291/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | KDM4E 917/4885ALDH1A1 4304/4885HPGD 2291/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | KDM4E 827/4885ALDH1A1 1925/4885HPGD 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.